Results 251 to 260 of about 466,412 (376)

Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications. [PDF]

Pharmacoeconomics
Campbell JA, Henson GJ, Ngwa VF, Ahmad H, Taylor BV, van der Mei I, MSBase Australian Researchers, Palmer AJ.   +7 more
europepmc   +1 more source

Effect of Honey Bee Venom on Experimental Autoimmune Encephalomyelitis (EAE) as a Model for Multiple Sclerosis (MS). [PDF]

Arch Razi Inst, 2021
Jelodar S, Zare Mirakabadi A, Oryan S, Mohammadnejad L.   +3 more
europepmc   +1 more source

An Assessment of Factors associated with high costs among Patients With Multiple Sclerosis (Ms) Receiving Disease-Modifying Drug (Dmd) Therapy [PDF]

, 2015
JC Locklear, Molly Frean, AL Phillips, Joseph Menzin   +3 more
openalex   +1 more source

Subventricular Zone Microstructure in Pediatric‐Onset Multiple Sclerosis

Annals of Neurology, Volume 97, Issue 5, Page 979-992, May 2025.
Objective The aim of this study was to explore the microstructural dynamics of the subventricular zone (SVZ) with aging and their associations with clinical disability and brain structural damage in pediatric‐onset multiple sclerosis (MS) patients. Methods One‐hundred and forty‐one pediatric‐onset MS patients (67 pediatric and 74 adults with pediatric ...
Monica Margoni, Loredana Storelli, Elisabetta Pagani, Paolo Preziosa, Damiano Mistri, Mor Gueye, Martina Rubin, Lucia Moiola, Massimo Filippi, Maria Assunta Rocca   +9 more
wiley   +1 more source

Review of evidence linking exposure to environmental stressors and associated alterations in the dynamics of immunosenescence (ISC) with the global increase in multiple sclerosis (MS). [PDF]

Immun Ageing
Bolton C.
europepmc   +1 more source

A protective variant of the autophagy receptor CALCOCO2/NDP52 in Multiple Sclerosis (MS). [PDF]

Autophagy, 2021
Di Rita A, Strappazzon F.
europepmc   +1 more source

Tocilizumab and multiple sclerosis: a causal relationship? Clinical Commentary on the case report entitled – MS arising during Tocilizumab therapy for rheumatoid arthritis [PDF]

, 2016
Manuel Comabella
openalex   +1 more source

Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study

Annals of Neurology, Volume 97, Issue 6, Page 1074-1087, June 2025.
Objective The neurodegenerative processes driving the build‐up of disability in progressive multiple sclerosis (P‐MS) have not been fully elucidated. Recent data link cellular senescence (CS) to neurodegeneration. We investigated for evidence of CS in P‐MS and sought to determine its pattern.
Dimitrios Papadopoulos, Roberta Magliozzi, Sara Bandiera, Ilaria Cimignolo, Elena Barusolo, Lesley Probert, Vassilis Gorgoulis, Richard Reynolds, Richard Nicholas   +8 more
wiley   +1 more source

Hyperpolarization Modulation of the T‐Type hCav3.2 Channel by Human Synenkephalin [1–53], a Shrew Neurotoxin Analogue without Paralytic Effects

Angewandte Chemie, EarlyView.
Human synenkephalin [1–53] (hSYN), an analogue peptide of shrew saliva neurotoxins, was synthesized and its structural characteristics studied. Synthetic hSYN potently activated the T‐type voltage‐gated Ca channel hCav3.2 but did not paralyze mealworms. These findings offer new insight into neurological disorder treatment and evolutionary mechanisms of
Ryo Fukuoka, Yusuke Yano, Nozomi Hara, Chihiro Sadamoto, Andres D. Maturana, Masaki Kita   +5 more
wiley   +2 more sources

Effects of robotic rehabilitation on fatigue experience, disability, and quality of life in patients with multiple sclerosis (MS): A systematic review and meta-analysis. [PDF]

Caspian J Intern Med
Naser Moghadasi A, Rastkar M, Mohammadifar M, Mohammadi A, Ghajarzadeh M.   +4 more
europepmc   +1 more source